- University of Oxford, in partnership with the Duke Clinical Research Institute, to assess effect of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease
- EMPA-KIDNEY will be part of the empagliflozin clinical development program which explores the efficacy and safety of Jardiance across a broad spectrum of patients and clinical conditions
PR Newswire
RIDGEFIELD, Conn. and INDIANAPOLIS, April 16, 2018